{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:18:48Z","timestamp":1787663928535,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Polymyxin B remains a key last-resort therapy for infections caused by multidrug-resistant Gram-negative bacteria. Nevertheless, its substantial pharmacokinetic (PK) variability and narrow therapeutic window pose significant challenges to dose individualization. Despite the availability of multiple published population pharmacokinetic (popPK) models, a comprehensive repository to enable model-informed precision dosing has not yet been established. Accordingly, this study aimed to develop a comprehensive library of polymyxin B popPK models to facilitate individualized treatment in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was performed to locate published population pharmacokinetic models of polymyxin B. Three bibliographic databases, namely, PubMed, Web of Science, and Embase, were searched through November 2025 without a lower date limit. For each eligible study, information was collected on study design, administered doses, blood-sampling schemes, structural model characteristics, parameter values, and covariate effects. Articles published in languages other than English, duplicate records, and studies based on nonparametric modeling approaches were excluded. The model database was constructed in R with the mrgsolve package, and an interactive Shiny platform was created to support exposure simulation and individualized model-informed dose prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-two studies were incorporated into the polymyxin B model repository. The study populations included patients receiving extracorporeal membrane oxygenation (two studies), patients undergoing continuous renal replacement therapy or related renal replacement modalities (four studies), and patients with severe burns, liver dysfunction, lung or renal transplantation, obesity, renal impairment, or advanced age, as well as healthy volunteers. The repository also incorporated subpopulations with clinically relevant covariates known to influence PK, such as renal function and obesity. Most polymyxin B popPK models were described by a two-compartment model with linear elimination. In 10 of the 22 studies, renal function metrics were found to significantly impact distribution or elimination PK parameters. Internal validation was reported for all included models, whereas only two studies evaluated model performance using external datasets. Exposure simulations showed marked differences across models, indicating that fixed standard dosing regimens may have limited ability to consistently achieve target therapeutic concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By harmonizing published population pharmacokinetic models in a single framework, this repository enables systematic exploration of model-based predictions across clinically relevant populations and may facilitate individualized polymyxin B therapy. However, given the complex clinical scenarios in critically ill patients, the heterogeneity of their physiological and pathological states, and the substantial interindividual PK variability of polymyxin B, further investigations are warranted to establish a more robust evidence base for precision dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1900585","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:23:44Z","timestamp":1787660624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A population pharmacokinetic model library for polymyxin B: clinical implementation of model-informed precision dosing"],"prefix":"10.3389","volume":"17","author":[{"given":"Shimin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fuyang Normal University Second Affiliated Hospital","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuyang Normal University Second Affiliated Hospital","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuyang Normal University Second Affiliated Hospital","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuyang Normal University Second Affiliated Hospital","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Hou","sequence":"additional","affiliation":[{"name":"Science and Education Department, Fuyang Normal University Second Affiliated Hospital","place":["Fuyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1019411","DOI":"10.3389\/fphar.2022.1019411","article-title":"Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: a prospective study","volume":"13","author":"Cai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.cmi.2023.05.018","article-title":"A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients","volume":"29","author":"Hanafin","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dks536","article-title":"A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies","volume":"68","author":"He","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","article-title":"Global threat of Carbapenem-Resistant gram-negative bacteria","volume":"12","author":"Jean","year":"2022","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/DDDT.S434919","article-title":"Model-Informed precision dosing of isoniazid: parametric population pharmacokinetics model repository","volume":"18","author":"Ju","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CPAA.S502272","article-title":"Parametric population pharmacokinetics model repository of rifampicin: model-informed individualized therapy","volume":"17","author":"Ju","year":"2025","journal-title":"Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01493-17","article-title":"Population pharmacokinetics of intravenous polymyxin B from clinical samples","volume":"62","author":"Kubin","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"727170","DOI":"10.3389\/fphar.2021.727170","article-title":"Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1111\/bcp.15855","article-title":"Population pharmacokinetics of polymyxin B in patients with liver dysfunction","volume":"89","author":"Li","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10928-024-09916-9","article-title":"A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver And\/Or kidney dysfunction","volume":"51","author":"Li","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0004425","DOI":"10.1128\/aac.00044-25","article-title":"Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria","volume":"69","author":"Li","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","article-title":"Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects","volume":"82","author":"Liu","year":"2021","journal-title":"J. Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13054-023-04522-6","article-title":"Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial","volume":"27","author":"Liu S.","year":"2023","journal-title":"Crit. Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1631\/jzus.B2200466","article-title":"Chinese consensus guidelines for therapeutic drug monitoring of polymyxin B, endorsed by the infection and chemotherapy committee of the shanghai medical association and the therapeutic drug monitoring committee of the Chinese pharmacological society","volume":"24","author":"Liu","year":"","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.2147\/DDDT.S425654","article-title":"Escitalopram personalized dosing: a population pharmacokinetics repository method","volume":"17","author":"Liu","year":"","journal-title":"Drug Des. Devel Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/jac\/dkv340","article-title":"Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins","volume":"71","author":"Lu","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106214","DOI":"10.1016\/j.ejps.2022.106214","article-title":"Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy","volume":"175","author":"Luo","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1128\/AAC.02445-15","article-title":"Characterization of polymyxin B biodistribution and disposition in an animal model","volume":"60","author":"Manchandani","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/pharmrev.120.000020","article-title":"Rescuing the last-line polymyxins: achievements and challenges","volume":"73","author":"Nang","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"108433","DOI":"10.1016\/j.pharmthera.2023.108433","article-title":"Bayesian prediction-based individualized dosing of anti-methicillin-resistant Staphylococcus aureus treatment: recent advancements and prospects in therapeutic drug monitoring","volume":"246","author":"Oda","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1007\/s40121-025-01213-3","article-title":"Optimizing polymyxin B therapy in critical care: pharmacokinetic insights and clinical outcomes in a retrospective cohort study","volume":"14","author":"Peng","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/jac\/dkad012","article-title":"Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients","volume":"78","author":"Pi","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.3390\/microorganisms8111814","article-title":"Performance of population pharmacokinetic models in predicting polymyxin B exposures","volume":"8","author":"Tam","year":"2020","journal-title":"Microorganisms"},{"key":"B25","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13054-023-04448-z","article-title":"Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study","volume":"27","author":"Tang","year":"2023","journal-title":"Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), european society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fphar.2020.00829","article-title":"Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"754844","DOI":"10.3389\/fphar.2021.754844","article-title":"Population pharmacokinetics of polymyxin B in Obese patients for resistant gram-negative infections","volume":"12","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01900-20","article-title":"Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency","volume":"65","author":"Wang","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"106693","DOI":"10.1016\/j.ijantimicag.2022.106693","article-title":"Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections","volume":"60","author":"Wang","year":"","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106599","DOI":"10.1016\/j.ijantimicag.2022.106599","article-title":"Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration","volume":"60","author":"Wang","year":"","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B33","doi-asserted-by":"publisher","first-page":"107099","DOI":"10.1016\/j.ijantimicag.2024.107099","article-title":"Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis","volume":"63","author":"Wang","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.2147\/IDR.S486169","article-title":"Pharmacokinetic changes and influencing factors of polymyxin B in different ECMO modes","volume":"17","author":"Xu","year":"2024","journal-title":"Infect. Drug Resist"},{"key":"B35","doi-asserted-by":"publisher","first-page":"107696","DOI":"10.1016\/j.burns.2025.107696","article-title":"Population pharmacokinetics and dosing optimisation of polymyxin B in patients with severe burns","volume":"51","author":"Yang","year":"","journal-title":"Burns"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1511088","DOI":"10.3389\/fphar.2025.1511088","article-title":"Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma concentration","volume":"16","author":"Yang","year":"","journal-title":"Front. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jcpt.13711","article-title":"The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation","volume":"47","author":"Ye","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.14576","article-title":"Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions","volume":"87","author":"Yu","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"975066","DOI":"10.3389\/fphar.2022.975066","article-title":"Pharmacokinetics\/Pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40262-025-01488-2","article-title":"A systematic review of pharmacokinetic studies of colistin and polymyxin B in adult populations","volume":"64","author":"Zamri","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/592577","article-title":"Pharmacokinetics of intravenous polymyxin B in critically ill patients","volume":"47","author":"Zavascki","year":"2008","journal-title":"Clin. Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1900585\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:23:45Z","timestamp":1787660625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1900585\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":41,"alternative-id":["10.3389\/fphar.2026.1900585"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1900585","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1900585"}}